Clinicopathological features of patients undergoing surgery for pancreatic cancer with very early postoperative recurrence

胰腺癌手术后早期复发患者的临床病理特征

阅读:1

Abstract

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy, with approximately 50% of patients experiencing recurrence within 1-year post-surgery. Very early recurrence (VER), defined as recurrence within 12 weeks, is an emerging concept. AIM: To investigate clinicopathological characteristics and predictive factors for VER in patients with PDAC. METHODS: A retrospective cohort study was conducted on 553 patients who underwent pancreatic surgery for PDAC at a single high-volume center between February 2019 and December 2024. Patients with VER (group 1, n = 28) were compared to those without (group 2, n = 251) after excluding 24 patients with inadequate surgical resection. Clinicopathological characteristics were compared using univariate and multivariate analyses, supplemented by random forest modeling to identify nonlinear patterns (P < 0.05). RESULTS: Group 1 patients were younger (65 ± 16.85 years vs 68 ± 9.58 years; P < 0.001) and had higher 6-month mortality (32.44% vs 14.77%; P = 0.032). Poorly differentiated tumors (G3) were the strongest predictor of VER (odds ratio = 2.43, 95% confidence interval: 0.88-5.34; P < 0.001, random forest feature importance: 0.35). Pancreatic head tumors (P = 0.031) and elevated red cell distribution width (P = 0.03) were associated with VER in univariate analysis. Sensitivity analysis confirmed imaging timing (4-8 weeks vs 8-12 weeks) did not significantly alter recurrence classification (P = 0.12). CONCLUSION: Poorly differentiated tumors are a key predictor of VER, linked to higher mortality. Machine learning enhances predictive accuracy, and molecular studies are needed to elucidate VER mechanisms. Tailored surveillance and multi-institutional validation are recommended.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。